The Progressive Supranuclear Palsy drugs in development market research report provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Progressive Supranuclear Palsy . Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued products.
GlobalData tracks 33 drugs in development for Progressive Supranuclear Palsy by 30 companies/universities/institutes. The top development phase for Progressive Supranuclear Palsy is preclinical with 13 drugs in that stage. The Progressive Supranuclear Palsy pipeline has 30 drugs in development by companies and three by universities/ institutes. Some of the companies in the Progressive Supranuclear Palsy pipeline products market are: Arvinas, UCB and New Amsterdam Sciences.
The key targets in the Progressive Supranuclear Palsy pipeline products market include Microtubule Associated Protein Tau, NADPH Oxidase 4, and Rho Kinase.
The key mechanisms of action in the Progressive Supranuclear Palsy pipeline product include Microtubule Associated Protein Tau Inhibitor with 14 drugs in Phase II. The Progressive Supranuclear Palsy pipeline products include five routes of administration with the top ROA being Oral and six key molecule types in the Progressive Supranuclear Palsy pipeline products market including Small Molecule, and Monoclonal Antibody.
Progressive Supranuclear Palsy overview
Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome, is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech, and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, and behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.
For a complete picture of Progressive Supranuclear Palsy ‘s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
